Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD])

Toru Suzuki, Eric M. Isselbacher, Christoph A. Nienaber, Reed E. Pyeritz, Kim A. Eagle, Thomas T. Tsai, Jeanna V. Cooper, James L. Januzzi, Alan C. Braverman, Daniel G. Montgomery, Rossella Fattori, Linda Pape, Kevin M. Harris, Anna Booher, Jae Kuen Oh, Mark Peterson, Vijay S. Ramanath, James B. Froehlich

Research output: Contribution to journalArticle

104 Scopus citations

Abstract

The effects of medications on the outcome of aortic dissection remain poorly understood. We sought to address this by analyzing the International Registry of Acute Aortic Dissection (IRAD) global registry database. A total of 1,301 patients with acute aortic dissection (722 with type A and 579 with type B) with information on their medications at discharge and followed for ≤5 years were analyzed for the effects of the medications on mortality. The initial univariate analysis showed that use of β blockers was associated with improved survival in all patients (p = 0.03), in patients with type A overall (p = 0.02), and in patients with type A who received surgery (p = 0.006). The analysis also showed that use of calcium channel blockers was associated with improved survival in patients with type B overall (p = 0.02) and in patients with type B receiving medical management (p = 0.03). Multivariate models also showed that the use of β blockers was associated with improved survival in those with type A undergoing surgery (odds ratio 0.47, 95% confidence interval 0.25 to 0.90, p = 0.02) and the use of calcium channel blockers was associated with improved survival in patients with type B medically treated patients (odds ratio 0.55, 95% confidence interval 0.35 to 0.88, p = 0.01). In conclusion, the present study showed that use of β blockers was associated with improved outcome in all patients and in type A patients (overall as well as in those managed surgically). In contrast, use of calcium channel blockers was associated with improved survival selectively in those with type B (overall and in those treated medically). The use of angiotensin-converting enzyme inhibitors did not show association with mortality.

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalAmerican Journal of Cardiology
Volume109
Issue number1
DOIs
StatePublished - Jan 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Suzuki, T., Isselbacher, E. M., Nienaber, C. A., Pyeritz, R. E., Eagle, K. A., Tsai, T. T., Cooper, J. V., Januzzi, J. L., Braverman, A. C., Montgomery, D. G., Fattori, R., Pape, L., Harris, K. M., Booher, A., Oh, J. K., Peterson, M., Ramanath, V. S., & Froehlich, J. B. (2012). Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). American Journal of Cardiology, 109(1), 122-127. https://doi.org/10.1016/j.amjcard.2011.08.012